Morgan Stanley lowered the firm’s price target on Integra LifeSciences to $24 from $37 and keeps an Underweight rating on the shares. An overall in line Q1 was “overshadowed” by another negative update on Boston facility commercialization, says the analyst, who continues to see Integra shares underperforming relative to peers over the next 12 months.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IART:
- Integra LifeSciences sees Q2 adjusted EPS 60c-65c, consensus 75c
- Integra LifeSciences lowers FY24 adj EPS view to $3.01-$3.11 from $3.15-$3.25
- Integra LifeSciences reports Q1 adjusted EPS 55c, consensus 55c
- Is IART a Buy, Before Earnings?
- Integra LifeSciences to Spotlight CereLink® Intracranial Pressure (ICP) Monitoring System at the American Association of Neurological Surgeons (AANS) Annual Scientific Meeting